Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming drug resistance in cancer, has been awarded the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its investigational therapy ENV-105 (carotuximab). The award recognizes the company's approach to restoring and extending the effectiveness of existing cancer treatments in metastatic prostate cancer and non-small cell lung cancer.
ENV-105 is an investigational neutralizing antibody being evaluated in combination with standard-of-care therapies. The recognition follows recently reported positive interim efficacy data from Kairos Pharma's ongoing Phase 2 trial of ENV-105 combined with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis demonstrated a statistically significant difference in progression-free survival between patients receiving the combination therapy and those receiving apalutamide alone, suggesting a potential breakthrough in addressing treatment resistance.
Based in Los Angeles, California, Kairos Pharma (NYSE American: KAPA) utilizes structural biology to target drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By reversing drug resistance, ENV-105 aims to restore the effectiveness of standard therapies across multiple cancer types, potentially improving outcomes for patients who have developed resistance to conventional treatments.
The award and the positive interim data underscore the importance of Kairos Pharma's work in cancer immunology. For investors and industry observers, the recognition may signal growing validation of the company's therapeutic approach and could enhance its visibility in the competitive biotech landscape. The full press release can be viewed at https://ibn.fm/GnUxn, and the latest updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The platform's reach includes editorial syndication to 5,000+ outlets and social media distribution, helping companies like Kairos Pharma gain recognition among investors and the public.
For readers, this news highlights ongoing advancements in cancer treatment that could eventually lead to new therapeutic options for patients with resistant forms of prostate and lung cancer. The recognition of ENV-105 also draws attention to the broader challenge of drug resistance in oncology, a major hurdle in cancer care. As Kairos Pharma continues its clinical development, the interim data and award may bolster confidence in its pipeline and attract further investment, potentially accelerating the path to regulatory approval and commercialization.
